L M Thøstesen1, J Kjaergaard2, G T Pihl1, N M Birk3, T N Nissen3, P Aaby4, A K G Jensen5, A W Olesen6, L G Stensballe7, D L Jeppesen3, C S Benn8,9, P-E Kofoed1. 1. Paediatric Department, Kolding Hospital, Kolding, Denmark. 2. Paediatric Department, Rigshospitalet, Copenhagen, Denmark. 3. Paediatric Department, Hvidovre Hospital, Hvidovre, Denmark. 4. Bandim Health Project, SSI, Copenhagen, Denmark. 5. CVIVA, Bandim Health Project, SSI & Section of Biostatistics, University of Copenhagen, Copenhagen, Denmark. 6. Department of Obstetrics and Gynaecology, Odense University Hospital, Odense, Denmark. 7. The Child and Adolescent Clinic, Rigshospitalet, Copenhagen, Denmark. 8. CVIVA, Bandim Health Project, SSI & OPEN, Institute of Clinical Research, University of Southern Denmark, Copenhagen, Denmark. 9. Odense University Hospital, Odense, Denmark.
Abstract
BACKGROUND: Studies have suggested that Bacillus Calmette-Guérin (BCG) vaccination may reduce the risk of allergic diseases, including atopic dermatitis. METHODS: The Danish Calmette Study was conducted 2012-2015. Within 7 days of birth new-borns were randomised 1:1 to BCG or no BCG. Exclusion criteria were gestational age <32 weeks, birth weight <1000 g, known immunodeficiency or no Danish-speaking parent. Data were collected through telephone interviews and clinical examinations until 13 months. RESULTS:Clinical atopic dermatitis was diagnosed in 466/2,052 (22.7%) children in the BCG group and 495/1,952 (25.4%) children in the control group (RR = 0.90 [95% confidence intervals 0.80-1.00]). The effect of neonatal BCG vaccination differed significantly between children with atopic predisposition (RR 0.84 (0.74-0.95)) and children without atopic predisposition (RR 1.09 [0.88-1.37]) (test of no interaction, P = .04). CONCLUSION: Among children with atopic predisposition, the number-needed-to-treat with BCG to prevent one case of atopic dermatitis was 21 (12-76).
RCT Entities:
BACKGROUND: Studies have suggested that Bacillus Calmette-Guérin (BCG) vaccination may reduce the risk of allergic diseases, including atopic dermatitis. METHODS: The Danish Calmette Study was conducted 2012-2015. Within 7 days of birth new-borns were randomised 1:1 to BCG or no BCG. Exclusion criteria were gestational age <32 weeks, birth weight <1000 g, known immunodeficiency or no Danish-speaking parent. Data were collected through telephone interviews and clinical examinations until 13 months. RESULTS: Clinical atopic dermatitis was diagnosed in 466/2,052 (22.7%) children in the BCG group and 495/1,952 (25.4%) children in the control group (RR = 0.90 [95% confidence intervals 0.80-1.00]). The effect of neonatal BCG vaccination differed significantly between children with atopic predisposition (RR 0.84 (0.74-0.95)) and children without atopic predisposition (RR 1.09 [0.88-1.37]) (test of no interaction, P = .04). CONCLUSION: Among children with atopic predisposition, the number-needed-to-treat with BCG to prevent one case of atopic dermatitis was 21 (12-76).
Authors: Valerie Acm Koeken; L Charlotte J de Bree; Vera P Mourits; Simone Jcfm Moorlag; Jona Walk; Branko Cirovic; Rob Jw Arts; Martin Jaeger; Helga Dijkstra; Heidi Lemmers; Leo Ab Joosten; Christine S Benn; Reinout van Crevel; Mihai G Netea Journal: J Clin Invest Date: 2020-10-01 Impact factor: 14.808
Authors: Gladymar Perez Chacon; Jessica Ramsay; Christopher G Brennan-Jones; Marie J Estcourt; Peter Richmond; Patrick Holt; Tom Snelling Journal: Cochrane Database Syst Rev Date: 2021-09-06
Authors: Bridget Freyne; Nicole L Messina; Susan Donath; Susie Germano; Rhian Bonnici; Kaya Gardiner; Dan Casalaz; Roy M Robins-Browne; Mihai G Netea; Katie L Flanagan; Toby Kollmann; Nigel Curtis Journal: J Infect Dis Date: 2020-06-11 Impact factor: 5.226
Authors: Nicole L Messina; Kaya Gardiner; Susan Donath; Katie Flanagan; Anne-Louise Ponsonby; Frank Shann; Roy Robins-Browne; Bridget Freyne; Veronica Abruzzo; Clare Morison; Lianne Cox; Susie Germano; Christel Zufferey; Petra Zimmermann; Katie J Allen; Peter Vuillermin; Mike South; Dan Casalaz; Nigel Curtis Journal: BMJ Open Date: 2019-12-15 Impact factor: 2.692
Authors: Niyati Lobo; Nathan A Brooks; Alexandre R Zlotta; Jeffrey D Cirillo; Stephen Boorjian; Peter C Black; Joshua J Meeks; Trinity J Bivalacqua; Paolo Gontero; Gary D Steinberg; David McConkey; Marko Babjuk; J Alfred Witjes; Ashish M Kamat Journal: Nat Rev Urol Date: 2021-06-15 Impact factor: 14.432